Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD9750 with or without other anticancer drugs in metastatic castration-resistant prostate cancer
NL-OMON61021Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2026
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of AZD9750 in metastatic castration-resistant prostate cancer (mCRPC) (3 arms), sponsored by AstraZeneca. Primary endpoints: Incidence of dose-limiting toxicities, Incidence of adverse events and serious adverse events and 3 more. Started Jul 2026; status: completed.
02
Drugs
AZD9750
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NL-OMON61021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61021.